Expert opinion on immunotherapy induced diabetes.

Sarra Smati, Perrine Buffier, Benjamin Bouillet, Françoise Archambeaud, Bruno Vergès, Bertrand Cariou

Journal: Annales d'endocrinologie 2019;79(5):545-549

PMID: 30126628

Full Text on Elsevier Science View on PubMed

Abstract

Immunotherapy often incurs side-effects, mainly involving the skin, digestive tract and endocrine system. The most frequent endocrine side-effects involve the pituitary and thyroid glands. Cases of insulin-dependent diabetes, whether autoimmune or not (type 1 or 1B) have been reported with PD-1/PD-L1 inhibitors, alone or in association with anti-CTLA-4 antibodies, and were systematically associated with sudden-onset insulinopenia, frequently leading to ketoacidosis or fulminant diabetes, requiring first-line insulin therapy. This adverse effect has not so far been reported with anti-CTLA-4 monotherapy.

Address: Department of endocrinology, l'institut du thorax, CHU Nantes, 44000 Nantes, France. Electronic address: [email protected].; Service d'endocrinologie, diabétologie, maladies métaboliques, CHU Dijon, hôpital François Mitterrand, 21034 Dijon cedex, France.; Service de médecine interne B - Endocrinologie, 87042 Limoges cedex, France.; Department of endocrinology, l'institut du thorax, CHU Nantes, 44000 Nantes, France.

DOI: 10.1016/j.ando.2018.07.006

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetes.html

Other Literature Sources:

https://scite.ai/reports/30126628

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD274-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Antibodies, Monoclonal, Consensus, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Immunotherapy, Prognosis